Background
==========

Vitamin D deficiency is a highly prevalent condition, present in approximately 30--50% of the general population \[[@B1]\], and may be as high as 100% in institutionalized elderly patients \[[@B2],[@B3]\]. Vitamin D supplementation is increasingly advised, but compliance with daily dosing regimens is low \[[@B4]\]. Because serum 25-hydroxyvitamin D~3~ (25(OH)D~3~), the functional indicator of vitamin D status, has a long half-life of about 2 months \[[@B5]\], there is great interest in intermittent dosing for patient convenience and long-term adherence. Administration of 100,000 IU of cholecalciferol (vitamin D~3~) every 4 months for 5 years showed a 22% reduction in the risk of osteoporotic fractures \[[@B6]\], similar to studies using a daily dose of 800 IU \[[@B7]\]. On the contrary, rapid increases in serum 25(OH)D from intermittent high doses of 500,000 IU of vitamin D~3~ once a year for 3--5 years in older women, have been shown to increase the risk of falls and fractures by 26% compared with the use of a placebo \[[@B8]\]. In clinical studies using high-dose regimens of up to 600,000 IU of vitamin D~3~, there has been surprisingly little concern for vitamin D toxicity. Plasma calcium and urinary calcium excretion both are recognized markers of vitamin D toxicity \[[@B5]\]. In the few clinical studies that have analyzed plasma calcium levels and/or urinary calcium excretion within a month after dosing, calcium levels were found to be unchanged or only slightly elevated within the reference range following a loading dose of 300,000 IU \[[@B9]\], 500,000 IU \[[@B10]\], 540,000 IU \[[@B11]\], or 600,000 IU \[[@B12],[@B13]\].

Here, we describe the pharmacokinetics of an accidental overdosing by 2,000,000 IU vitamin D~3~ in two elderly nursing home patients and discuss safety issues from single massive oral doses of vitamin D~3~.

Case presentation
=================

In Waelwick, a nursing home near Nijmegen, all residents receive osteoporosis prophylaxis with oral vitamin D~3~ doses of 100,000 IU three times a year as a lyophilized solution (2 mL vitamin D~3~ aquosum FNA, 50,000 IU/mL). Two nursing home patients each received an accidental single overdose of 2,000,000 IU vitamin D from a whole bottle of a concentrated vitamin D~3~ solution (40 mL vitamin D~3~ aquosum FNA 50,000 IU/mL). The pharmacy department was surprised by the order for 25 new bottles immediately after the dose, as the two 40-mL bottles would have lasted for half of a year of treatment for the patients at the ward. It then became clear that an overdose had been given. For safety reasons, we immediately started biochemical and clinical monitoring of both patients. Plasma calcium, phosphate, creatinine, and 25(OH)D levels were measured from 1 h after dosing up to 106 days (case 1) and 71 days (case 2) (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). Vitamin D~3~ was measured at time points 1 h, 0.5, 1, 2, 8, and 14 days after dosing (Figure [1](#F1){ref-type="fig"}). Because of the nature of this study, baseline concentrations (prior to dosing) were lacking. Unfortunately, we lacked the opportunity for measuring 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D (because of limited availability of plasma material), parathyroid hormone (PTH) and bone turnover markers (lack of the appropriate blood containers or pre-analytical conditions), and urinary calcium excretion (lack of urine collection).

![**Time course of plasma calcidiol and calcium concentrations, as well as semi-quantitative measurements of plasma vitamin D**~**3**~**(cholecalciferol), after a single oral dose of 2,000,000 IU of vitamin D to two nursing home residents.** The asterisk indicates the individual calcium measurements that show a biologically significant difference from baseline concentrations. Note the time-scale differences between the vitamin D~3~ (cholecalciferol) and the upper plots.](2050-6511-15-57-1){#F1}

###### 

Biochemical values from single high-dose vitamin D3 administration in two cases

                                             **Reference range**   **1 h**   **5.5 h**   **1d**     **2d**     **3d**     **4d**     **8d**     **11d**   **14d**   **22d**   **29d**   **36d**   **43d**   **60d**    **71d**   **106d**
  --------------------- -------------------- --------------------- --------- ----------- ---------- ---------- ---------- ---------- ---------- --------- --------- --------- --------- --------- --------- ---------- --------- ----------
  Case 1                Calcidiol (nmol/L)   50-200                59        **224**     **395**    **448**                          **527**              **522**   **403**   **323**   **318**   **283**              **203**   131
  Calcium (mmol/L)      2.20-2.65            2.52                  2.51      2.57        2.64       **2.67**   2.64       **2.68**              2.63      2.57      2.45      2.5       2.5                 2.43       2.43      
  Phosphate (mmol/L)    0.80-1.40            1.08                  1.09      1.05        1.30       1.13       1.14       1.37                  1.32      1.01      1.00      0.98      0.97                           0.96      
  Creatinine (μmol/L)   60-110               64                    65        66          68         69         73         69                    77        75        71        69        63        66        75         65        
  Case 2                Calcidiol (nmol/L)   50-200                77                    **326**    **354**                          **422**              **405**   **363**   **322**   **324**   **255**              **233**    
  Calcium (mmol/L)      2.20-2.65            2.46                            **2.69**    **2.73**   **2.68**   **2.69**   **2.66**   **2.70**   2.57      2.59      2.50      2.49      2.59                2.57                 
  Phosphate (mmol/L)    0.80-1.40            0.91                            1.20        1.06       1.12       1.05       1.13       1.02       1.07      0.82      0.82      0.89      0.87                **0.79**             
  Creatinine (μmol/L)   50-90                **45**                          51          **44**     55         54         52         52         **49**    52        **41**    50        54                  **45**               

Values outside the reference range are indicated in bold. h, hours; d, days. Conversion factors: calcidiol (mg/dL = 0.4 × mmol/L), calcium (mg/dL = 4 × mmol/L), phosphate (mg/dL = 3.1 × mmol/L), creatinine (mg/dL = 0.01 × μmol/L).

Measurements of plasma 25(OH)D concentrations, as well as semi-quantitative measurement of vitamin D~3~ (monitoring peak area), were performed using liquid chromatography-tandem mass spectrometry as previously described \[[@B14]\]. Plasma calcium, phosphate, and creatinine levels were measured on a routine clinical chemistry analyzer (Modular; Roche Diagnostics, Mannheim, Germany). Changes of biological significance were calculated from reference change (RCV, at a 95% confidence interval) according to the formula RCV = Z × 2^1/2^$({CV}_{a}^{2}+{CV}_{a}^{2})$^1/2^\[[@B15]\], where Z = 1.96 (i.e., the Z-score for 95% confidence), CV~a~ = analytical variation, and CV~i~ = intra-individual variation. For calcium, CV~a~ and CV~i~ were 1.5% and 1.9%, respectively \[[@B16]\].

Case 1 was a 90-year-old man of Caucasian origin, with normal kidney function (estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD) equation \>60 mL/min), and an absence of significant pathology. He did not report any clinical signs or symptoms of vitamin D toxicity. His plasma calcium was 2.52 mmol/L 1 h after dosing and showed a non-significant increase from day 1 to day 8, with a maximum of 2.68 mmol/L at day 8. After 8 days, plasma calcium levels fell to within the reference range (2.2--2.65 mmol/L) (Figure [1](#F1){ref-type="fig"}). At first measurement, 1 h after gift, vitamin D3 was already detected. The vitamin D~3~ peak area showed a prompt increase with the highest peak area already at the second measurement, 5.5 h after dosing, followed by a rapid decrease to undetectable levels at day 14. Plasma 25(OH)D~3~ concentrations also were already markedly increased 5.5 h after dosing, but rose more slowly than vitamin D~3~, reaching a maximum of 527 nmol/L at day 8. Over the following 3-month period, 25(OH)D~3~ concentrations decreased by 50% over an approximately 50-day period. At the end of the 106-day follow-up period, the patient's 25(OH)D~3~ concentration was 113 nmol/L and fell within the laboratory reference range (50--200 nmol/L). Plasma phosphate and creatinine levels showed a modest increase within the reference range (Table [1](#T1){ref-type="table"}).

Case 2 relates to a 95-year-old woman of Caucasian origin, with normal kidney function (MDRD \>60 mL/min) and an absence of significant pathology. She did not report any clinical signs or symptoms of vitamin D toxicity. Her plasma calcium was 2.46 mmol/L 1 h after dosing and showed a biologically significant increase from day 1 to day 11 with a maximum of 2.73 mmol/L at the second day. After 11 days, plasma calcium levels dropped to within the reference range of 2.2--2.65 mmol/L (Figure [1](#F1){ref-type="fig"}). Vitamin D~3~ peak area was highest at the first measurement opportunity, being 1-day post-dose, followed by a rapid decrease to undetectable levels after day 14. Plasma 25(OH)D~3~ concentrations also were already markedly increased 1 day after dosing, but rose more slowly than vitamin D~3~, reaching a maximum of 422 nmol/L at day 8. At the end of the 71-day follow-up period, the 25(OH)D~3~ concentration was 233 nmol/L, with an approximate 50% decrease from the highest level being still above the upper normal limit of 200 nmol/L. Plasma phosphate and creatinine levels both showed a modest increase within the reference range (Table [1](#T1){ref-type="table"}).

Discussion
==========

Pharmacokinetic studies in human volunteers given a single large oral dose of 100,000 IU of vitamin D~3~ indicate that serum vitamin D~3~ and 25(OH)D~3~ levels peak on days 1 and 7, respectively \[[@B17],[@B18]\]. The vitamin D~3~ concentrations fell rapidly, being close to baseline by day 7, with a much slower fall of the 25(OH)D~3~ concentrations. Plasma calcium levels did not rise at any time, and no subject experienced hypercalcemia at any of the measured time points \[[@B17]\]. The pharmacokinetic profiles of our two cases resembled those from the 100,000 IU study and emphasize the importance of measuring 25(OH)D and calcium concentrations over the first 14 days for identifying the maximum blood concentrations. The half-life of the plasma 25(OH)D levels of about 50 days in case 1 is comparable to a half-life of about 2 months as described previously \[[@B5]\]. The relatively normal 25(OH)D~3~ concentrations in our nursing home residents (59 nmol/L in case 1 and 77 nmol/L in case 2) at the first measurement (1 h post-dosing) can be explained as the result of previous osteoporosis prophylaxis treatments with 100,000 IU of oral vitamin D~3~. However, we cannot exclude the possibility that the plasma 25(OH)D concentrations were already increased 1 h after the high dose of vitamin D~3~, implicating that the baseline 25(OH)D values in both cases actually may have been lower.

The toxicity of vitamin D in daily administration has been studied extensively. The present view is that hypercalcemia is the hazard criterion for vitamin D \[[@B19]\]. Thus, vitamin D toxicity is supposed to be inseparable from hypercalcemia. Hypercalcemia does not occur with daily doses up to 40,000 IU of vitamin D~3~ and serum levels of 25(OH)D~3~ up to 500 nmol/L, well above naturally occurring levels of 25(OH)D~3~\[[@B20]\]. Most patients with an overdose of vitamin D~3~ are not seen by a physician until they are admitted to the emergency department with clinical signs of intoxication, such as life-threatening dehydration, after a prolonged period of oral intake of high-dose vitamin D, either from contaminated food components \[[@B21],[@B22]\] or supplements with errors in manufacturing and/or labeling \[[@B23],[@B24]\].

Much less is known about the toxicity of vitamin D~3~ following a single high oral dose of vitamin D~3~. In studies using 300,000 IU \[[@B9]\], 540,000 IU \[[@B11]\], and 600,000 IU \[[@B12],[@B13]\] of oral vitamin D~3~, no adverse effects were noted and plasma calcium levels or urinary calcium excretion did not change, or only slightly increased for a short period of time, with all cases remaining within the physiological range. In contrast to these reassuring data, Sanders et al. \[[@B8]\] found a significant increase in the risk of falls (+15%) and fractures (+26%) in a randomized controlled trial with an annual dose of 500,000 IU vitamin D~3~ for 3--5 years in older women compared with placebo. Falls and fractures occurred especially within the first 3 months following the annual dose of vitamin D~3~. In that study, plasma calcium levels and urinary calcium excretion were not measured; however, bearing in mind the former data, it is unlikely that hypercalcemia occurred in the study. These unexpected findings led Rossini et al. \[[@B13],[@B25]\] to investigate dose-dependent short-term effects on bone turnover markers of a single bolus of vitamin D~3~. A single dose of 600,000 IU of vitamin D~3~ increased serum C-terminal telopeptide of type 1 collagen and cross-linked N-telopeptide of type 1 collagen significantly at day 1, attained a peak increment greater than 50% at day 3, and subsequently decreased almost back to baseline values at day 90, without statistically significant changes in plasma calcium \[[@B13]\]. Their results indicate that the use of oral megadoses greater than 100,000 IU of vitamin D may be counterproductive and that the safety issues surrounding vitamin D dosing should not be limited to early markers of vitamin D toxicity as plasma hypercalcemia or increased urinary calcium excretion \[[@B13],[@B25]\]. A possible explanation is the fact that the level of 1,25 dihydroxy-vitamin D is regulated much stronger in the endocrine system than in the autocrine system of vitamin D \[[@B5]\]. If the plasma level of calcidiol (the substrate of the autocrine vitamin D system) increases sharply after a loading dose that deviates too much from the maximum physiological daily dose with sunlight (20,000 IU), this might result in toxic intracellular calcitriol levels in the autocrine vitamin D system without toxic circulating calcitriol levels in the endocrine system of vitamin D and without hypercalcemia. If that is the case, we need other markers than hypercalcemia to prove vitamin D toxicity in the autocrine system, such as bone turnover markers \[[@B13]\]. In any case, more studies are needed to evaluate potential adverse effects of high-dose vitamin D treatment on bone metabolism in relation to fracture risk and risk of falls.

The present study displays some limitations. We lacked the opportunity for studying other relevant parameters in the risk assessment for vitamin D~3~, such as measurement of urinary calcium excretion and plasma levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, PTH, and bone turnover markers. Because of the nature of this study, baseline concentrations (prior to dosing) of biochemical parameters such as plasma vitamin D~3~, 25(OH)D, and calcium were lacking.

Conclusion
==========

In our two patients, the massive single overdose of 2,000,000 IU of vitamin D~3~ did not result in immediate clinical and biochemical toxicity requiring hospitalization, with only slightly elevated plasma calcium levels in the first 2 weeks. However, toxicity in the long term cannot be excluded as an annual dose of 500,000 IU of vitamin D~3~ for several years has shown an increased risk of fractures. This may implicate that markers other than plasma calcium measurement, such as bone turnover markers, are needed to assess the safety of high doses of vitamin D in the long term. Clearly, the safety of high-dose vitamin D supplementation warrants further study. To prevent a similar error in the future, the use of multiple-dose bottles were replaced by smaller single-unit dose formulations of 25.000 IU/mL. In general, we believe that available formulations of vitamin D~3~ should not exceed 100,000 IU, as long as the safety of high doses of vitamin D in the long term has not been established.
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